Keros Therapeutics, Inc. KROS
What this company does
Written from the business description in Keros Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 20 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | 0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 |
| Net income $B | 0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | 0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | 2.30 | −5.00 | −5.20 | −4.15 | −2.52 | −2.93 | −6.08 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | 19.9 | −41.5 | −50.2 | −40.2 | −23.3 | −37.4 | · |
| Shares out B | 0.02 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 7 of 19 fiscal years. 48 checks could not be computed.